RT Journal Article
SR Electronic
T1 Continuous Positive Airway Pressure effect on visual acuity in patients with type 2 diabetes and Obstructive Sleep Apnoea: a multicentre randomised controlled trial
JF European Respiratory Journal
JO Eur Respir J
FD European Respiratory Society
SP 1801177
DO 10.1183/13993003.01177-2018
A1 Sophie D. West
A1 Benjamin Prudon
A1 Joan Hughes
A1 Rajen Gupta
A1 Seid B. Mohammed
A1 Stephen Gerry
A1 John R. Stradling
A1 for the ROSA Trial investigators
YR 2018
UL http://erj.ersjournals.com/content/early/2018/08/16/13993003.01177-2018.abstract
AB Objective: We sought to establish whether CPAP for OSA in people with type 2 diabetes and diabetic macular oedema (DME) improved visual acuity.Methods: We randomly assigned 131 eligible patients aged 30–85 years from 23 UK centres with significant DME causing visual impairment (LogMAR letters identified, ≥ 39–≤ 78, score 0.92–0.14) plus severe OSA on screening to either: usual ophthalmology care (n=67) or usual ophthalmology care plus CPAP (n=64) for 12 months.Results: Mean age of participants was 64 years, 73% male, mean BMI 35.0 kg·m−2. Mean 4% oxygen desaturation index was 36/hour. There was no significant difference in the visual acuity at twelve months between the CPAP group and the control group, mean LogMAR (95%CI) 0.33 (0.29, 0.37) versus 0.31 (0.27, 0.35), p=0.39, and no significant correlation between change in LogMAR and average CPAP use. The median daily CPAP use (sd, range) was 3.33 (2.25, 0–7.93) hours at three months, 3.19 (2.54, 0–8.07) hours at six months and 3.21 (2.7, 0–7.98) hours at twelve months.Conclusion: CPAP therapy for OSA did not improve visual acuity in people with type 2 iabetes and diabetic macular oedema compared to usual care alone over 12 months.FootnotesThis manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article.Conflict of interest: Dr. West has nothing to disclose.Conflict of interest: Dr. Prudon reports grants and other from ResMed UK Ltd, during the conduct of the study.Conflict of interest: Dr. Hughes has nothing to disclose.Conflict of interest: Dr. Gupta reports other from Bayer, non-financial support from Novartis, personal fees from Bayer , outside the submitted work.Conflict of interest: Mr. Mohammed has nothing to disclose.Conflict of interest: Mr. Gerry has nothing to disclose.Conflict of interest: Dr. Stradling reports grants from Resmed Foundation, during the conduct of the study; personal fees from Resmed UK, personal fees from Bayer Germany, outside the submitted work; .